Dr.ObesityLA said:

The useful move here is to separate what is established from what is widely repeated.

Coming at Dr.ObesityLA’s question from a different direction. The pharmacokinetics explain nearly every practical question asked here. Albumin binding above 99% slows clearance enough to make weekly dosing possible; a terminal half-life near a week means four to five weeks to steady state and therefore a four-week titration interval; subcutaneous bioavailability around 89% means injection site barely matters. Those three facts answer most timing questions before they are asked.

Worth separating that from the pharmacology, which this thread keeps folding into the same question. They behave differently and the advice does not transfer.

The figures, for anyone assembling their own picture. If you are comparing against somebody else’s result, check that you are comparing the same measurement taken the same way. Most of the apparent contradictions in these threads dissolve at that step.

One thing that is still open after Dr.ObesityLA’s answer:

Which effects tachyphylax and which persist, because the answer explains why tolerability improves while the appetite effect keeps working?

TrialTracker_MD said:

If you are comparing against somebody else’s result, check that you are comparing the same measurement taken the same way.

I am going to disagree with the direction of travel here. The thread has converged on the tidiest answer rather than the best-supported one, and those are not the same thing.

TrialTracker_MD said:

If you are comparing against somebody else’s result, check that you are comparing the same measurement taken the same way.

Agreed, with the usual condition: that holds for the average and this board is a collection of individuals. A population claim and a personal prediction are different things and get quoted interchangeably.